Company / Total Debt
Amneal Pharmaceuticals, Inc. Total Debt History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Debt
$2.6B
FY2025
5-year range
$2.4B / $2.7B
FY2021-FY2025
Trend
+7.8%
vs FY2024
Sector context
#19 of 83
Health Care
What the data says
Amneal Pharmaceuticals, Inc.'s total debt of $2.6B is higher than 77% of companies in the Health Care sector (FY2025). Total Debt returned to growth in FY2025 after 4 years of decline, reaching $2.6B.
Based on SEC 10-K filings.
$2.6B in FY2025 with a 5-year CAGR of -1.5%. Top quartile in the Health Care sector.
Increased from $2.4B to $2.6B over the past 2 years.
Health Care sector context is included.
Total Debt over time
Growth rates
- 3-Year CAGR
- -0.6%
- 5-Year CAGR
- -1.5%
- 10-Year CAGR
- -
Sector benchmark
Bottom 23% in Health CareTop 77% of 83This company $2.6B Sector average $6.2B
▼
-58.2% below sector average
Key checks
Key Insights
- 5-year CAGR of -1.5%, indicating a declining trend.
- In FY2025, total debt increased 7.8% year-over-year.
- Ranks #19 out of 83 companies in the Health Care sector.
- Peak total debt was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score 1.22 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total DebtValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.6B | +7.8% |
| FY2024 | $2.4B | -1.4% |
| FY2023 | $2.4B | -7.7% |
| FY2022 | $2.6B | -3.3% |
| FY2021 | $2.7B | -2.5% |
| FY2020 | $2.8B | +5.7% |
| FY2019 | $2.6B | -0.8% |
| FY2018 | $2.7B | +83.6% |
| FY2017 | $1.4B | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026